Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

Ivan Barilar, Simone Battaglia, Emanuele Borroni, Angela Pires Brandão, Alice Brankin, Andrea Maurizio Cabibbe, Joshua Carter, Darren Chetty, Daniela María Cirillo, Pauline Claxton, David A. Clifton, Ted Cohen, Jorge Coronel, Derrick W. Crook, Viola Dreyer, Sarah G. Earle, Vincent Escuyer, Lucilaine Ferrazoli, Philip W. Fowler, George F. Gao, Jennifer L. Gardy, Saheer E. Gharbia, Kelen Teixeira Ghisi, Arash Ghodousi, Ana Lúıza Gibertoni Cruz, Louis Grandjean, Clara Grazian, Ramona Groenheit, Jennifer L. Guthrie, Wencong He, Harald Hoffmann, Sarah Hoosdally, Martin Hunt, Zamin Iqbal, Nazir Ismail, Lisa Jarrett, Lavania Joseph, Ruwen Jou, Priti Kambli, Rukhsar Khot, Jeff Knaggs, Anastasia Koch, Donna Kohlerschmidt, Samaneh Kouchaki, Alexander S. Lachapelle, Ajit Lalvani, Simon Grandjean Lapierre, Ian F. Laurenson, Brice Letcher, Wan-Hsuan Lin, Chunfa Liu, Dongxin Liu, Kerri M. Malone, Ayan Mandal, Mikael Mansjö, Daniela Matias, Graeme Meintjes, Flávia de Freitas Mendes, Matthias Merker, Marina Mihalic, James Millard, Paolo Miotto, Nerges Mistry, David Moore, Kimberlee A. Musser, Dumisani Ngcamu, Hoang Ngoc Nhung, Stefan Niemann, Kayzad Nilgiriwala, Camus Nimmo, Max R. O’Donnell, Nana Okozi, Rosângela Siqueira de Oliveira, Shaheed Vally Omar, Nicholas I. Paton, Tim Peto, Juliana Maíra Watanabe Pinhata, Sara Plesnik, Zully M. Puyén, Marie Sylvianne Rabodoarivelo, Niaina Rakotosamimanana, Paola M. V. Rancoita, Priti Rathod, Esther Robinson, Gillian Rodger, Camilla Rodrigues, Timothy C. Rodwell, Aysha Roohi, David Santos-Lázaro, Sanchi Shah, Grace Smith, Thomas A. Kohl, Walter Solano, Andrea Spitaleri, Adrie J. C. Steyn, Philip Supply, Utkarsha Surve, Sabira Tahseen, Nguyễn Thụy Thương Thương, Guy ThwaitesNature Communications 2024 · DOI

TL;DR

This study presents a comprehensive quantitative analysis of antibiotic resistance in Mycobacterium tuberculosis by linking whole-genome sequencing data to precise Minimum Inhibitory Concentration (MIC) measurements for 13 drugs across over 15,000 clinical isolates. The findings reveal hundreds of new genetic variants associated with resistance and susceptibility, significantly advancing the development of rapid, genetics-based diagnostics and personalized treatment strategies for tuberculosis.

What Problem Does This Paper Address?

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health threat, exacerbated by the rise of drug-resistant strains. Current molecular diagnostics often provide binary (susceptible/resistant) results, failing to capture the nuances of resistance, such as sub-threshold MIC elevations. These subtle increases can be clinically significant, predisposing strains to higher-level resistance and treatment failure. Furthermore, existing diagnostics may miss emerging resistance determinants, particularly for newer drugs. This paper aims to bridge this gap by providing a quantitative, genetics-based understanding of Mtb antibiotic resistance, moving beyond binary classifications to inform more precise diagnostics and treatment.

Methods

The researchers employed a multi-pronged approach:

  • Whole Genome Sequencing (WGS): They performed WGS on 15,211 Mtb clinical isolates.
  • Quantitative Microtiter Plate Assay: A validated microtiter plate assay was used to determine the Minimum Inhibitory Concentration (MIC) for 13 different antibiotics. This is a key differentiator from binary susceptibility testing.
  • Multivariable Linear Mixed Model: This statistical model was central to the analysis, linking genomic mutations (SNPs, insertions, deletions) within target genes and their upstream regions to the quantitative MIC values. The model also controlled for population structure and technical variations across different testing sites.
  • Candidate Gene Approach: The analysis focused on a predefined set of candidate genes known or suspected to be involved in antibiotic resistance, along with 100 base pairs upstream of each gene.

Datasets

The primary dataset consists of 15,211 Mycobacterium tuberculosis clinical isolates collected from 23 countries across five continents. This dataset was characterized by:

  • Whole Genome Sequencing (WGS) data.
  • Quantitative Minimum Inhibitory Concentration (MIC) data for 13 drugs.
  • Phenotypic susceptibility data (binary susceptible/resistant) was also available.

After quality control and filtering, the final dataset used for the genotype/phenotype intersection comprised approximately 12,350 isolates. The paper also references the 2021 WHO catalog for tuberculosis for comparison.

Key Insights and Ideas

  • Beyond Binary: The study powerfully demonstrates the value of quantitative MIC measurements over binary susceptibility testing. Subtle shifts in MIC, even below established critical concentrations, are genetically driven and clinically relevant.
  • Uncovering New Determinants: The research identified a substantial number of novel genetic variants associated with both increased resistance and, intriguingly, increased susceptibility to various drugs.
  • Hypersensitivity as a Therapeutic Clue: The discovery of mutations linked to hypersensitivity opens up new avenues for optimizing drug regimens, potentially by leveraging these genetic markers.
  • Complex Resistance Mechanisms: The findings highlight that resistance isn't always a simple additive effect of mutations. Interactions between mutations and the influence of genetic background (lineage) play significant roles.
  • A Curated Resource: The generated dataset and findings serve as a valuable, high-quality resource for developing and validating future machine-learning-based drug resistance prediction algorithms.

Key Results

  • 492 unique MIC-elevating variants were identified across 13 drugs.
  • 91 mutations were linked to hypersensitivity (decreased MIC).
  • For rifampicin, 35 mutations were identified with effects ranging from 1.0 to 9.0 log2MIC increases, including seven novel resistance-associated mutations outside the traditional RRDR.
  • Ethionamide showed the most unique variants associated with reduced susceptibility (163).
  • Linezolid had the fewest unique variants associated with reduced susceptibility (8).
  • The study found that promoter mutations were frequently implicated in resistance, sometimes with effects comparable to or exceeding those of gene-body mutations.
  • Interactions between mutations were identified, where the combined effect of two mutations was greater than the sum of their individual effects, particularly for ethambutol and rifampicin resistance.

Limitations and Future Work

The authors acknowledge several limitations:

  • Limited representation of newer drugs: The dataset had a lower number of isolates resistant to newer drugs like bedaquiline, clofazimine, linezolid, and delamanid.
  • Lineage representation: Lineages 5 and 6 of Mtb, prevalent in sub-Saharan Africa, were underrepresented.
  • Exclusion of large indels: Insertions and deletions larger than 50 bp were excluded from the primary analysis due to modeling limitations.
  • ECOFF validation: While concordance with existing methods was shown, the extensive validation of ECOFFs against all other methods is ongoing.
  • Minor alleles: The potential influence of minor alleles at resistance sites, even after filtering, remains a consideration.

Future work suggested includes:

  • Understanding sub-ECOFF mutations: Further research is needed to determine if mutations with MIC effects below ECOFFs lead to increased treatment failure or relapse, and if rapid molecular assays should be developed to detect them.
  • Leveraging hypersensitivity mutations: Investigating the clinical relevance of hypersensitivity mutations for optimizing drug regimens.
  • Expanding the catalog: Continued collection of resistant strains and the use of advanced methods like GWAS, directed evolution, and machine learning to identify resistance determinants for drugs where the current catalog is incomplete.
  • Clinical validation: The generated dataset is intended to be a crucial resource for developing and validating machine-learning algorithms for predicting drug resistance in clinical settings.

Summary updated

Abstract

The World Health Organization has a goal of universal drug susceptibility testing for patients with tuberculosis. However, molecular diagnostics to date have focused largely on first-line drugs and predicting susceptibilities in a binary manner (classifying strains as either susceptible or resistant). Here, we used a multivariable linear mixed model alongside whole genome sequencing and a quantitative microtiter plate assay to relate genomic mutations to minimum inhibitory concentration (MIC) in 15,211 Mycobacterium tuberculosis clinical isolates from 23 countries across five continents. We identified 492 unique MIC-elevating variants across 13 drugs, as well as 91 mutations likely linked to hypersensitivity. Our results advance genetics-based diagnostics for tuberculosis and serve as a curated training/testing dataset for development of drug resistance prediction algorithms.
BibTeX
@inproceedings{barilar2024quantitative,
  author = {Ivan Barilar and Simone Battaglia and Emanuele Borroni and Angela Pires Brandão and Alice Brankin and Andrea Maurizio Cabibbe and Joshua Carter and Darren Chetty and Daniela María Cirillo and Pauline Claxton and David A. Clifton and Ted Cohen and Jorge Coronel and Derrick W. Crook and Viola Dreyer and Sarah G. Earle and Vincent Escuyer and Lucilaine Ferrazoli and Philip W. Fowler and George F. Gao and Jennifer L. Gardy and Saheer E. Gharbia and Kelen Teixeira Ghisi and Arash Ghodousi and Ana Lúıza Gibertoni Cruz and Louis Grandjean and Clara Grazian and Ramona Groenheit and Jennifer L. Guthrie and Wencong He and Harald Hoffmann and Sarah Hoosdally and Martin Hunt and Zamin Iqbal and Nazir Ismail and Lisa Jarrett and Lavania Joseph and Ruwen Jou and Priti Kambli and Rukhsar Khot and Jeff Knaggs and Anastasia Koch and Donna Kohlerschmidt and Samaneh Kouchaki and Alexander S. Lachapelle and Ajit Lalvani and Simon Grandjean Lapierre and Ian F. Laurenson and Brice Letcher and Wan-Hsuan Lin and Chunfa Liu and Dongxin Liu and Kerri M. Malone and Ayan Mandal and Mikael Mansjö and Daniela Matias and Graeme Meintjes and Flávia de Freitas Mendes and Matthias Merker and Marina Mihalic and James Millard and Paolo Miotto and Nerges Mistry and David Moore and Kimberlee A. Musser and Dumisani Ngcamu and Hoang Ngoc Nhung and Stefan Niemann and Kayzad Nilgiriwala and Camus Nimmo and Max R. O’Donnell and Nana Okozi and Rosângela Siqueira de Oliveira and Shaheed Vally Omar and Nicholas I. Paton and Tim Peto and Juliana Maíra Watanabe Pinhata and Sara Plesnik and Zully M. Puyén and Marie Sylvianne Rabodoarivelo and Niaina Rakotosamimanana and Paola M. V. Rancoita and Priti Rathod and Esther Robinson and Gillian Rodger and Camilla Rodrigues and Timothy C. Rodwell and Aysha Roohi and David Santos-Lázaro and Sanchi Shah and Grace Smith and Thomas A. Kohl and Walter Solano and Andrea Spitaleri and Adrie J. C. Steyn and Philip Supply and Utkarsha Surve and Sabira Tahseen and Nguyễn Thụy Thương Thương and Guy Thwaites},
  title = {{Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-023-44325-5},
}
Figure